Cardiovascular Risk Assessment and Management

Recommendations for Lipid Testing

The American College of Cardiology/American Heart Association recommends against measuring advanced lipid parameters, including NMR-derived particle size and density, beyond a standard fasting lipid profile for cardiovascular risk assessment, as they provide no demonstrated benefit, with a Class III (No Benefit) recommendation 1, 2
The European Heart Journal suggests that standard lipid measurements, such as LDL-C, non-HDL-C, remain the primary treatment targets, as they are supported by decades of clinical trial evidence demonstrating mortality and morbidity reduction 4, 5
The American College of Cardiology/American Heart Association explicitly states that Apo E genotyping is NOT recommended for routine cardiovascular risk assessment, with very narrow exceptions for specific diagnostic purposes only, as no data demonstrate that genotype testing alters management or improves outcomes for prevention of coronary heart disease 1, 2, 6

Apo E genotyping may be considered for diagnosis of dysbetalipoproteinemia (Type III hyperlipoproteinemia) in patients presenting with severe combined hyperlipidemia, where Apo E2 homozygosity is the underlying cause, according to the European Heart Journal 4, 7
Genetic screening in families with familial hypercholesterolemia may be used in specialized lipid clinics, as recommended by the European Heart Journal 4, 7

The American College of Cardiology/American Heart Association recommends measuring total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides as the foundation of cardiovascular risk assessment, and calculating non-HDL cholesterol as a secondary target, particularly in patients with elevated triglycerides or metabolic syndrome 1, 2, 4, 5
Validated risk calculators, such as the Framingham Risk Score, ASCVD Risk Calculator, or SCORE in Europe, should be used to determine 10-year cardiovascular risk, as recommended by the European Heart Journal and the American College of Cardiology 4, 5
Therapeutic interventions should focus on proven targets, with LDL-C reduction with statins remaining the cornerstone of cardiovascular risk reduction, associated with a 22% reduction in cardiovascular mortality and morbidity for every 40 mg/dL (1.0 mmol/L) reduction in LDL-C, according to the European Heart Journal 7